The role of lipids, lipoproteins and lipoprotein(a) [Lp(a)] in coronary artery disease (CAD) is known but the role of major apolipoproteins (apos) other than apo A-I and apo B remains unclear. In this study, using immunoturbidimetry we have estimated serum levels of total cholesterol, HDL-C, LDL-C, triglyceride, LDL-apoB and all major apos; A-I, A-II, B, C-II, C-III and E, in 751 healthy Indian subjects (470 men and 281 women, age 25-65 years), determined their percentiles, and established reference intervals. The effects of age, smoking and alcohol on all these analytes were also evaluated. This is the first study to provide reference intervals for all apos, in both sexes from a general population. The percentiles and the reference intervals have clinical relevance and will be useful in assessing the risk of CAD in patients with hyperlipidemia and other diseases. J Atheroscler Thromb, 2005; 12: 251-259.
Introduction
In clinical practice, levels of lipids (cholesterol and triglycerides) and lipoproteins (HDL cholesterol [HDL-C] and LDL cholesterol [LDL-C]) are measured to diagnose lipid disorders (dyslipidemia), to assess the risk of associated cardiovascular disease (CVD), and to decide subsequent treatments (1) . Elevated levels of lipoprotein(a) [Lp(a)] have also been associated with coronary heart disease (CHD) (2) . In addition, a number of epidemiological studies have indicated that serum apolipoprotein (apo) concentrations and the risk of CHD are related (3, 4) . Apolipoproteins are the major protein components of lipoproteins. By binding to lipoprotein receptors present on various cells they mediate lipid transfer and thus serve to maintain the lipid and lipoprotein levels in circulation (5) .
Apolipoproteins that can be used in clinical laboratory tests include apolipoprotein (apo) A-I, apo A-II, apo B, apo C-II, apo C-III, and apo E (5). Apo A-I is the major protein component of HDL-C and is involved in the reverse transport of cholesterol. Apo-AII may inhibit hepatic triacylglycerol lipase (an enzyme responsible for hydrolysis in the liver) at high concentrations. While an elevated level of serum apo-AI is inversely associated with CHD risk, an elevated level of apo B, a protein component of LDL-C, is associated with increased CHD risk. In addition to serum concentrations, an increased apo B to apo A-I ratio (apo B/apo A-I) is also considered a marker for CHD. Apo-CII is the activator for lipoprotein lipase (LPL), the enzyme responsible for the removal of triglycerides from very low density lipoprotein (VLDL) (5) . In contrast, apo-CIII inhibits LPL. Apo E confers receptor-binding properties to VLDL and remnants for both LDL-C (apo B and apo E receptor) and a specific apo E receptor in the liver (5) . Apolipoproteins can be assayed in laboratories using immunoturbidimetry, immunonephelometry, single radial immunodiffusion and ELISA. Despite the potential clinical utility of apolipoprotein measurements, use of apo assays has been limited. This can be attributed to a number of factors namely: the lack of standardization, a suit-able reference database, and an automated assay suitable for use in routine clinical laboratory tests. However the recent establishment of reference intervals (RI) for apo A-I and apo B using World Health Organization-International Federation of Clinical Chemistry (WHO-IFCC) reference materials and a traceable measurement system (6) , for Lp(a), (7) and for apo E and apo CIII by the STANISLAS cohort study (8, 9) , has encouraged the measurement of these apolipoproteins in regular clinical laboratories.
With the increasing incidence of CHD in India, testing for apolipoproteins along with lipids and lipoproteins would be of help in assessing the associated risk of CVD. However, there is no reference data available among Indian populations. It was therefore felt necessary to conduct this study, which would serve as a reference database for our population and would be useful in evaluating the clinical relevance of apo AII, apo CII, apo CIII and apo E, about which, unlike apo AI and apo B, very little is known.
Subjects
A total of 751 subjects in the age group 25-65 yrs were included in the study. Of these, 470 were males and 281 were females. The subjects selected were those who attended a health checkup program at our hospital and were healthy i.e. not suffering from diabetes, hypertension, or CHD and not on medication for lowering lipid levels. Complete details of the subjects concerning physical history, family history, and smoking and alcohol habits were obtained. Subjects reporting any regular or occasional usage of cigarettes or tobacco were classified as smokers and those reporting little or no consumption of alcohol were included in the no-alcohol group. The ethics committee of our institution approved the study. The blood samples were collected after an overnight fast of 12 hours in plain tubes. Serum samples were stored at -70°C until analyzed.
Methods
Lipid analysis -The analysis was carried out on an automated analyzer, Beckman Synchron Cx7. Total cholesterol (TC) and triglyceride (TG) levels were determined enzymatically. HDL-C and LDL-C cholesterol levels were estimated directly. The concentration of the apolipoproteins apo A-I, A-II, apo B, apo C-II, apo C-III, and apo E as well as Lp(a) were determined by immunoturbidimetry. The reagents needed for the assay were provided by Daiichi Pure Chemicals (Tokyo, Japan) and Accurex India Pvt. Ltd. The level of LDL-apoB, a marker for small dense LDL (sdLDL), was calculated as described by Hattori et al. (10) . The instrument was calibrated using the calibrators provided by Daiichi. Control sera (lyophilized Daiichi control and pool sera) were included in each batch of samples analyzed. As part of External quality assurance, our laboratory is enrolled with the proficiency testing surveys of the College of American Pathologists.
Statistical Analysis
Lipid, lipoprotein and apolipoprotein levels were expressed as the mean ± SD. Lp(a) levels were expressed as the median. A value of p < 0.05 was considered to be statistically significant. We used SPSS software [version 10 .0] for the data analysis. The data was further categorized according to gender, age groups, and smoking and alcohol habits. The normality of the data was tested using the one-sample Kolmogorov-Smirnov test. A normal distribution was seen for analytes like TC, LDL-C, LDLapoB, LDL-C/LDL-apoB, apoB, apoB/apoAI and apoC-II/apoC-III. The remaining analytes showed a non-normal distribution. For analytes exhibiting a normal distribution, an independent samples t-test was applied whereas for non-normal analytes Mann-Whitney's U-test was used. The same statistical methods were employed to evaluate the influence of smoking and alcohol consumption on all these analytes. However, when the data was categorized according to the various age groups, ANOVA (for normal analytes) and Kruskal-Wallis tests (for non-normal analytes) were used. As many parameters displayed non-Gaussian distributions, non-parametric methods were used for calculating the reference intervals. Thus, percentiles are quoted rather than limits based on calculations involving the mean and SD. The results for the reference samples were arranged in ascending order and assigned rankings such that the lowest value is ranked 1 and the largest, n. The limits that enclose 95% of the reference population were estimated by identifying the rank number corresponding to the 2.5th percentile (r1) and the 97.5th percentile (r2) as follows: r1 = 0.025 (n + 1) r2 = 0.975 (n + 1). The value corresponding to rank r1 is the lower reference limit and the value corresponding to r2 is the upper reference limit respectively. The 90% confidence interval (CI) for the limits depends on the sample and was determined. Table 1 shows the concentrations of the various analytes in both males and females. The body mass index (BMI) was 25.3 kg/mt 2 in males and 24.8 kg/mt 2 in females. Sex-related differences were observed for all the analytes except total cholesterol, apo A-II and apo E levels. Significant age-related differences were also observed ( Table  2) for total cholesterol, LDL-apoB, apo B, apo A-I and apo C-II levels in both men and women. In all the age groups, HDL-C and apo A-I levels were higher in women than in men. However, HDL-C levels did not vary significantly across the various age groups in either sex. The total cholesterol/HDL-C ratio (TC/HDL-C) and apo C-II/ apo C-III ratio differed significantly in both men and women across the various age groups. The effects of cigarette and alcohol consumption on these analytes were also evaluated (Tables 3 and 4 ). Overall data showed that the HDL-C level, apo A-I level and apo A-I/apo A-II ratio were significantly lower in smokers than non-smokers, whereas the triglyceride level, apo C-II level, apo C-III level and apoB/apoA-I ratio were significantly higher in smokers. When the data was further categorized by gender, triglyceride levels showed significant increases in male smokers, while apo C-III, apo C-II/apo C-III, apo E and triglyceride levels were significantly elevated in men who consumed alcohol.
Results
The levels of TC, TG, HDL-C, LDL-C, and six apolipoproteins and their ratios that define specific percentiles are presented ( Table 5 ). As per the NCEP ATP III guidelines (1), a total cholesterol concentration of 200-239 mg/dl is classified as borderline high and a level > 240 mg/dl as high. These concentrations of total cholesterol fell at the 75th and the 90th percentiles respectively in both men and women. The NCEP decisional concentration for HDL-C (< 40 mg/dl) fell at the 25th percentile for men and at the 10th percentile for women; the apo A-I values were approximately equal to 111 mg/dl for men and 109 mg/ dl for women. Similarly, the decisional concentration for LDL-C (130 mg/dl and 160 mg/dl) in our study fell at the 75th and 90th percentile for men and 75th and 95th percentile for women. The apo B values corresponding to the same percentiles were 111 mg/dl and 126 mg/dl for men and 104.5 mg/dl and 125.8 mg/dl for women. The LDL-apo B values corresponding to these same percentiles were 85.11 mg/dl and 96.19 mg/dl (75th and 90th percentile respectively for men), and 80.9 mg/dl and 99.27 mg/dl (75th and 95th percentile respectively for women). Triglyceride levels > 150 mg/dl were observed in the 75th percentile in men and 90th percentile in women. The median Lp(a) levels were significantly elevated in women compared to men. The levels did not vary with age, smoking or drinking habits Apo A-II levels in different percentiles across the various age groups in both men and women did not show much variation. The levels of apo C-II and apo C-III were higher in men than in women and showed a gradual increase in different percentiles across the various age groups in both sexes. However, the levels of apo C-II decreased in men aged 55 yrs and older. The levels of apo E did not vary much across the 5th to 95th percentile in men or women. However, the 2.5th percentile was lower in men and the 97.5th percentile was lower in women.
Discussion
Reference intervals for apo A-I and apo B and this clinical application have been well established using WHO-IFCC reference material in different populations using a variety of immunochemical methods with a degree of accuracy and precision required for assessing risk for CAD (11, 12) . Noma et al. (13) and Sakurabayashi et al. (14) have established reference intervals for all major apos in the Japanese population using an immunoturbidimetric assay. As part of a large, cross-sectional investigation, the Rochester Family Heart Study estimated levels of lipids, lipoproteins, and apolipoproteins in 446 males and 538 females (5-90 yrs of age) using a radioimmunoassay (15) . In the present study, we have established reference intervals for all major apos on the basis of our findings (Table 6 ) using the immunoturbidimetric assay. Additionally, the reference intervals for lipids and lipoproteins are also presented.
Consistent with our previous findings (16), the upper limits for the total cholesterol level, LDL-C level, and TC/ HDL-C ratio obtained in this study were much higher than values obtained in our laboratory, which are based on IFCC guidelines. Similarly, the lower limits for HDL-C were much lower than reported values. The levels were also lower than the levels obtained in the STANISLAS Cohort study (8) [ Table 7 ]. These observations are consistent with the low HDL-C levels found in Asians (17) , and in our population (16) where the prevalence was about 22.68%. Also according to the Coronary Artery Disease among Indians study, optimal HDL-C levels are present in only 14% of Asian Indian men and 5% of Asian Indian women (17). Sniderman et al. (18) first reported hyperapobetalipoproteinemia that is characterized by an increased LDL-apo B level with a normal LDL-C level often observed in myocardial infarction. The LDL-C/LDLapo B ratio reflects the level of sdLDL, which is an important risk factor for CHD. The LDL-apo B levels were estimated using the formula developed by Hattori et al. (10) . The mean LDL-apo B level observed by Hattori et al. (10) in a population-based Suita study (n = 1,514) was 91.8 ± 0.7, versus 72 ± 16.67 in our study. However, the LDL-C/LDL-apo B ratio was 1.39 ± 0.01 as compared to 1.6 ± 0.16 observed in our study, probably indicating the low prevalence of sdLDL in our population as compared to the Suita study. Our previous small study, which was done using the Lipoprint system (Quantimetrix), on healthy, normolipemic physicians from our hospital showed the presence of sdLDL in at least 50% of the subjects. (19) . The pattern of a low level of HDL and high levels of triglycerides and small dense LDL among Asian Indians is consistent with our observation (16, 19) and published reports from others (20) and denotes atherogenic dyslipidemia. Atherogenic dyslipidemia is associated with metabolic syndrome and may be responsible for accelerated atherosclerosis. Asian Indians have a high predisposition to metabolic syndrome that includes risk factors like abdominal obesity, insulin resistance, glucose intolerance, hypertriglyceridemia, low levels of HDL-C, and hypertension (20) . Currently, the clinical usefulness of all major apo assays remains to be evaluated. WHO-IFCC has standardized reference materials for the estimation of apo A-I and apo B and population results have been subsequently published (6, 11, 12) . The prospective Quebec Cardiovascular study (21) showed the importance of apo B in the estimation of coronary risk; the AMORIS study (4) suggested that apo B, apo B/apo A-I ratio, and apo A-I should be regarded as highly predictive in the evaluation of cardiac risk.
The clinical utility of other apos viz: apo A-II, apo C-II, apo C-III and apo E, is hampered by the lack of a suitable reference database. The apo E levels established in the STANISLAS Cohort study are higher than our findings (8) . Reference intervals for all six apos were determined. The recorded levels showed significant age and gender-related differences for most of the apos. The numbers of females having smoking and consuming alcohol were much lower than the males. Smoking did not show any major effect on the apo levels, however apo C-III and apo E levels were higher among men who consumed alcohol. The reference intervals determined in this study cannot be directly compared to studies published by Noma et al. (13) and Sakurabayashi et al. (14) because in these studies the mean ± SD was used as the reference interval and not percentiles. Also, the percentiles published in the Rochester Family Heart Study (15) were determined using a Radioimmunoassay and thus could not be compared. The levels of Lp(a) in our population were much higher than those reported by Sakurabayashi et al. (14) in the Japanese population. A Lp(a) level > 30 mg/dl is considered to be the threshold for influencing therapeutic decisions. In our study, we found the levels present up to the 75th percentile to be within this threshold in both men and women. The review article by Chopra and Wasir (22) also reports Lp(a) levels > 30 mg/dl in 25% of Asian Indians, though in whites this value is 17%. The review also states that levels are roughly twice as high in Asian Indians than Caucasians, Malays, and Chinese residents of Singapore. This is the first report to describe percentiles and reference intervals for all the major apos in addition to lipids, lipoproteins and Lp(a), in a large number of Indian adults of both sexes in the age range of 25-65 years from the general population, using commercially available reagents for automated analyzers. These percentiles will facilitate the identification of persons in the highest and lowest percentiles for their age and gender. In addition, the reference intervals established in this study will provide a basis for comparison with levels observed in patients with various pathological conditions and thus allow evaluation of the clinical relevance of these apolipoproteins in our population.
